TY - JOUR
T1 - Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival
AU - Lucas, Calixto Hope G.
AU - Vasudevan, Harish N.
AU - Chen, William C.
AU - Magill, Stephen T.
AU - Braunstein, Steve E.
AU - Jacques, Line
AU - Dahiya, Sonika
AU - Rodriguez, Fausto J.
AU - Horvai, Andrew E.
AU - Perry, Arie
AU - Pekmezci, Melike
AU - Raleigh, David R.
N1 - Publisher Copyright:
©dCrossed D sign
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive and poorly understood malignant neoplasm. Even in the setting of multimodal therapy, the clinical course of MPNST is frequently marked by metastatic conversion and poor overall prognosis, with optimal treatment paradigms for this rare tumor unknown. Methods: We reviewed the medical records and histopathology of 54 consecutive patients who were treated at University of California San Francisco between 1990 and 2018. Results: Our cohort consisted of 24 male and 30 female patients (median age 38 years).
AB - Background: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive and poorly understood malignant neoplasm. Even in the setting of multimodal therapy, the clinical course of MPNST is frequently marked by metastatic conversion and poor overall prognosis, with optimal treatment paradigms for this rare tumor unknown. Methods: We reviewed the medical records and histopathology of 54 consecutive patients who were treated at University of California San Francisco between 1990 and 2018. Results: Our cohort consisted of 24 male and 30 female patients (median age 38 years).
KW - FCrossed D sign©dCrossed D sign©ration Nationale des Centres de Lutte Contre Le Cancer
KW - clinical outcomes
KW - immunohistochemistry
KW - malignant peripheral nerve sheath tumor
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85126637169&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdaa131
DO - 10.1093/noajnl/vdaa131
M3 - Article
AN - SCOPUS:85126637169
SN - 2632-2498
VL - 2
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdaa131
ER -